These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35760971)

  • 1. Extended infusion of piperacillin-tazobactam versus intermittent infusion in critically ill egyptian patients: a cost-effectiveness study.
    Naiim CM; Elmazar MM; Sabri NA; Bazan NS
    Sci Rep; 2022 Jun; 12(1):10882. PubMed ID: 35760971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
    Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
    Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ; Cappelletty DM;
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
    Lodise TP; Lomaestro B; Drusano GL
    Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
    Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
    Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
    Arnold HM; Hollands JM; Skrupky LP; Smith JR; Juang PH; Hampton NB; McCormick S; Reichley RM; Hoban A; Hoffmann J; Micek ST; Kollef MH
    Ann Pharmacother; 2013 Feb; 47(2):170-80. PubMed ID: 23341160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.
    Lee GC; Liou H; Yee R; Quan CF; Neldner K
    Clin Ther; 2012 Dec; 34(12):2297-300. PubMed ID: 23195962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis.
    Fawaz S; Barton S; Nabhani-Gebara S
    BMC Infect Dis; 2020 Jun; 20(1):430. PubMed ID: 32563242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
    Brunetti L; Poustchi S; Cunningham D; Toscani M; Nguyen J; Lim J; Ding Y; Nahass RG
    Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-Infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center.
    Cutro SR; Holzman R; Dubrovskaya Y; Chen XJ; Ahuja T; Scipione MR; Chen D; Papadopoulos J; Phillips MS; Mehta SA
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4470-5. PubMed ID: 24867975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.
    McCormick H; Tomaka N; Baggett S; Heierman T; LaFosse J; Gilbert S; Imhof K
    Am J Health Syst Pharm; 2015 Jun; 72(11 Suppl 1):S25-30. PubMed ID: 25991590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
    Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
    Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Escherichia coli clinical isolates.
    Sumi CD; Heffernan AJ; Naicker S; Cottrell K; Wallis SC; Lipman J; Harris PNA; Sime FB; Roberts JA
    J Antimicrob Chemother; 2022 Oct; 77(11):3026-3034. PubMed ID: 36031790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
    Bao H; Lv Y; Wang D; Xue J; Yan Z
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
    Yusuf E; Spapen H; Piérard D
    J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.
    Patel GW; Patel N; Lat A; Trombley K; Enbawe S; Manor K; Smith R; Lodise TP
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):236-40. PubMed ID: 19500529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and evidence for extended infusion of piperacillin-tazobactam.
    Kaufman SE; Donnell RW; Hickey WS
    Am J Health Syst Pharm; 2011 Aug; 68(16):1521-6. PubMed ID: 21817083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.
    Yang H; Zhang C; Zhou Q; Wang Y; Chen L
    PLoS One; 2015; 10(1):e0116769. PubMed ID: 25575030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.